Table 1.
Patient characteristics
| < 60 years (N = 124) | ≥ 60 years (N = 138) | |
|---|---|---|
| Age in years: mean (SD) | 44.1 (11.5) | 70.5 (6.5) |
| Female | 52% | 47% |
| White | 81% | 94% |
| Insurance type | ||
| Medicaid | 30 (24%) | 2 (1%) |
| Medicare | 13 (11%) | 106 (77%) |
| Commercial insurance | 77 (62%) | 30 (22%) |
| No insurance | 4 (3%) | 0 (0%) |
| Clinical characteristics | ||
| Chronic obstructive pulmonary disease | 5 (4%) | 18 (13%) |
| Diabetes | 9 (7%) | 28 (20%) |
| Acute or chronic renal failure | 12 (10%) | 23 (17%) |
| Coronary artery disease/heart failure | 6 (5%) | 18 (13%) |
| Charlson comorbidity Index > 1 | 15.8% | 60.1% |
| Received steroid during hospitalization | 51.6% | 48.6% |
| Received insulin during hospitalization | 24.2% | 31.2% |
| Body mass index < 30 (kg/m2) | 79 (68%) | 92 (74%) |
| Hemoglobin median (25th, 75th) | 9.3 (8,10.4) | 9.3 (8.3,10.4) |
| White blood cell median (25th, 75th) | 18.3 (5.5, 45.1) | 10.1 (2.3, 45.6) |
| Lactate dehydrogenase median (25th, 75th) | 396 (278, 655) | 328 (212, 502) |
| Cytogenetic risk category | ||
| Favorable | 29 (24.4%) | 4 (3.1%) |
| Intermediate | 66 (55.5%) | 95 (72.5%) |
| Unfavorable | 24 (20.2%) | 32 (24.4%) |
| Induction treatment | ||
| 7 + 3 | 10 (8.1%) | 51 (37.0%) |
| 7 + 3 + 3 | 101 (81.5%) | 58 (42.0%) |
| 7 + 3 + other | 9 (7.3%) | 24 (17.4%) |
| Glycemic profiles (mg/dL) | ||
| Hospitalization mean glucose (mean (SD)) | 111.6 (16.4) | 121.7 (25.9) |
| Hospitalization glycemic variability: glucose SD (mean (SD)) | 26.8 (18.6) | 33.0 (22.8) |
SD, standard deviation; 7 + 3 + 3, cytarabine+anthracycline+etoposide